Clinical Trial Update: The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial [Phase 3]

View source ↗

Summary

Phase 3 randomized controlled trial evaluating nighttime dosing of mirabegron, solifenacin, tolterodine, or oxybutynin on nocturia and related urinary outcomes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Detrol (tolterodine)
• Ditropan (oxybutynin)
• Myrbetriq (mirabegron)
• Vesicare (solifenacin succinate)

Snippet

Sponsor: Far Eastern Memorial Hospital | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: NOT_YET_RECRUITING